IMPORTANCE Pediatric pseudotumor cerebri syndrome pathophysiology is complex and not well delineated. Therefore, it is important to identify potential contributors or targets underlying the primary pathogenesis for its development.

OBJECTIVE To report cases highlighting the association of pediatric pseudotumor cerebri syndrome with adrenal insufficiency.

DESIGN, SETTING, AND PARTICIPANTS This noncontrolled, observational case series included pediatric patients diagnosed with pseudotumor cerebri syndrome and adrenal insufficiency at an urban academic children's hospital in Houston, Texas, from June 2015 to October 2019.

MAIN OUTCOMES AND MEASURES Monitoring optic nerve edema by clinical examination, fundus photography, and optical coherence topography images of the optic nerve.

RESULTS Data were collected from 5 pediatric patients (age range, 5-10 years) diagnosed with pseudotumor cerebri syndrome and adrenal insufficiency. One was a girl, all were White and prepubertal. Three patients had unrecognized glucocorticoid exposure. All patients had bilateral optic nerve edema that was initially treated with acetazolamide or topiramate, but cortisol functional testing by either 8 AM cortisol or cosyntropin stimulation tests revealed a diagnosis of central adrenal insufficiency. Treatment with physiological doses of hydrocortisone resulted in resolution of optic nerve edema and clinical symptoms of pseudotumor cerebri syndrome, as well as a shorter time receiving medical therapy.

CONCLUSIONS AND RELEVANCE In this case series, adrenal insufficiency was associated with both primary and secondary prepubertal pediatric pseudotumor cerebri syndrome. As a potential target specific to causative mechanism, physiologic hydrocortisone therapy resolved the condition. To date, there remains a global unawareness among clinicians about the suppressive outcome that glucocorticoids may have on the developing hypothalamic-pituitary-adrenal axis, resulting in adrenal insufficiency and so-called episodic pseudotumor cerebri syndrome in young children. Ophthalmologists and pediatric subspecialists should implement cortisol testing via either 8 AM cortisol or cosyntropin stimulation tests at initial evaluation of all children with pseudotumor cerebri syndrome and risk factors for adrenal insufficiency, no predisposing causes, or nonresponse to conventional treatment. Further management and treatment should be in combination with ophthalmology and endocrine services.
Pseudotumor cerebri syndrome (PTCS) is characterized by elevated intracranial pressure (ICP), relatively normal neuroimaging results, and normal cerebrospinal fluid panel results. The classic ocular finding of PTCS is papilledema. Two distinct criteria for the diagnosis of PTCS exist: the modified Dandy criteria, which uses a threshold lumbar puncture opening pressure (OP) greater than 25 cm H₂O, and the revised PTCS criteria, which uses an OP greater than 28 cm H₂O (>25 cm H₂O in children who are sedated or nonobese)⁴.

The presence of PTCS in adults and children who are postpubertal is linked to female sex and obesity; in younger children who are prepubertal, these factors are not as relevant,⁵-⁶ suggesting puberty is a central factor in distinguishing the pathophysiology of pediatric PTCS.⁷ A neuroendocrine model of PTCS with association with the hypothalamic-pituitary-adrenal axis (HPAA) has been proposed.⁸,⁹ However, no cause-and-effect association with adrenal insufficiency (AI) has been established. We describe pediatric PTCS cases with papilledema and cortisol testing consistent with central AI.

Methods

The study is compliant with all existing regulations; written informed consent was obtained from patients’ parents, as well as ethical approval from the Baylor College of Medicine institutional review board. All patients were referred to Texas Children’s Hospital in Houston with optic nerve edema between June 2015 and October 2019, diagnosed with PTCS using existing criteria,¹ and followed up with ocular examinations and optical coherence tomography imaging (eMethods in the Supplement).¹⁰ Because of concerns of glucocorticoid (GC) withdrawal and/or the inability to resolve chronic PTCS in an otherwise healthy child, cortisol testing was longitudinally obtained (eMethods in the Supplement). Adrenal insufficiency was defined as an 8 AM cortisol test result of less than 6 μg/dL (to convert to nanomoles per liter, multiply by 27.588) or a peak cortisol level less than 17 μg/dL after a 1-μg cosyntropin stimulation low-dose Synacthen test (LDST); normal functioning was defined as an 8 AM cortisol level greater than 13 μg/dL or a peak cortisol level greater than 20 μg/dL.¹¹ Each case was initially treated with acetazolamide or topiramate; physiologic hydrocortisone therapy (6-9 mg/m²/d) was initiated with AI diagnosis.¹²

Cases are presented individually. Mean values were calculated without software. No statistical software was used for data analysis.

Results

Five pediatric cases, including 1 girl, presented with low-grade papilledema without visual acuity loss. All 5 were White and did not have obesity. Diagnosis of definite PTCS with papilledema was consistent with the revised PTCS criteria, with exception of the patient with case 1, who was considered to have probable PTCS (Table). The following are case details (eMethods and eTable in the Supplement).

Case 1

An 8-year-old boy with a history of asthma, allergic rhinitis, eczema, and recent headaches presented with bilateral optic nerve edema. A PTCS workup demonstrated a partial empty sella and an OP of 24 cm H₂O. Four months prior, he had discontinued intranasal GC and reduced his use of a beclomethasone inhaler. Administration of acetazolamide improved but did not resolve his papilledema (Figure). One year later, he had a normal LDST result. Inhaled beclomethasone was discontinued 2 years after the diagnosis, worsening his papilledema despite acetazolamide use. An 8 AM cortisol test result was consistent with AI, and hydrocortisone was initiated. In 8 weeks, his papilledema resolved, and his acetazolamide was titrated to discontinuation.

Case 2

A 5-year-old boy with a history of eczema presented with bilateral optic nerve edema coinciding with the completion of 3 months of trimacbinolone cream use. A PTCS workup included normal neuroimaging results, with a partially empty sella and an elevated OP. His LDST result was abnormal with no other pituitary deficiencies, and treatment was deferred. He received topiramate (because of an acetazolamide intolerance), and his papilledema resolved in 2 months. Topiramate was tapered off after 15 months, with papilledema recurring 3 months later. After an 8 AM cortisol test diagnosing AI, hydrocortisone was started. Within 8 weeks, the patient’s papilledema resolved, and topiramate was discontinued with no recurrence (eFigure 1 in the Supplement).

Case 3

A 4-year-old boy with esotropia and headaches presented with bilateral optic nerve edema and had an assessment with findings consistent with PTCS. Acetazolamide was started, but symptoms worsened despite increasing dosages, with repeated lumbar puncture OPs greater than 45 cm H₂O. Meges-
trol had notably been discontinued 3 weeks prior. An 8 AM cortisol test result and an LDST result confirmed AI. After hydrocortisone therapy, PTCS symptoms resolved, and acetazolamide was discontinued within 4 months. Eventually, hydrocortisone was discontinued without recurrence.

**Case 4**
A 5-year-old girl was referred for optic nerve swelling. Her evaluation confirmed PTCS, and despite acetazolamide use, her mild papilledema continued. After 16 months, an 8 AM cortisol test and LDST results confirmed AI. Following initiation of hydrocortisone, her papilledema resolved (eFigure 2 in the Supplement).

**Case 5**
A 10-year-old boy with short stature presented with bilateral optic nerve edema and had workup results consistent with PTCS. Despite a 2-year course of fluctuating acetazolamide dosages, mild papilledema persisted. Endocrine evaluation showed low 8 AM cortisol and thyroid function test results, consistent with AI and central hypothyroidism. Following hormonal therapy, acetazolamide was discontinued in 4 months with papilledema resolution and no recurrence.

### Table. Clinical Features of Pediatric Pseudotumor Cerebri Syndrome Case Series

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Case</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td></td>
<td>Male</td>
<td>Male</td>
<td>Male</td>
<td>Female</td>
<td>Male</td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
<td>Non-Hispanic White</td>
<td>Hispanic White</td>
<td>Non-Hispanic White</td>
<td>Non-Hispanic White</td>
<td>Non-Hispanic White</td>
</tr>
<tr>
<td>Age at diagnosis, y</td>
<td></td>
<td>8</td>
<td>5</td>
<td>4</td>
<td>5</td>
<td>10</td>
</tr>
<tr>
<td>BMI at diagnosis, z score</td>
<td></td>
<td>1.16</td>
<td>−0.62</td>
<td>−1.37</td>
<td>−0.43</td>
<td>0.22</td>
</tr>
<tr>
<td>Pubertal (Tanner) stage</td>
<td></td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Risk factor</td>
<td></td>
<td>Beclomethasone dipropionate inhaler; mometasone nasal spray</td>
<td>Topical triamcinolone for eczematosus lesions</td>
<td>Megestrol acetate</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Presenting symptoms</td>
<td></td>
<td>Intermittent headaches</td>
<td>Headaches, nausea, and emesis</td>
<td>Cranial nerve VI palsy, headache, nausea, and emesis</td>
<td>None</td>
<td>Headache and vision changes</td>
</tr>
<tr>
<td>Pseudotumor cerebri syndrome diagnostic testing</td>
<td></td>
<td>Opening pressure, cm H2O</td>
<td>24</td>
<td>32</td>
<td>&gt;45*</td>
<td>34*</td>
</tr>
<tr>
<td>Magnetic resonance imaging brain result</td>
<td></td>
<td>Normal with slight posterior bilateral ocular flattening; partial empty sella</td>
<td>Normal with partial empty sella</td>
<td>Normal with bilateral flattening of posterior globes; inversion of optic nerve heads</td>
<td>Normal</td>
<td>Normal</td>
</tr>
<tr>
<td>Modified Frisen grade, OD/OS</td>
<td></td>
<td>+2/+2</td>
<td>+2/+2</td>
<td>+1/+1</td>
<td>+2/+2</td>
<td>+1-2/+1-2</td>
</tr>
<tr>
<td>Pharmacologic treatment</td>
<td></td>
<td>Maximum acetazolamide dose, mg/kg/d</td>
<td>14</td>
<td>13.4</td>
<td>88.2</td>
<td>20.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maximum topiramate dose, mg/kg/d</td>
<td>NA</td>
<td>30</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cortisol output on diagnostic cortisol testing</td>
<td>8 AM, μg/dL</td>
<td>5.8</td>
<td>4.1</td>
<td>&lt;0.2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Peak 1-μg cosyntropin stimulation, μg/dL</td>
<td>NA</td>
<td>NA</td>
<td>1.9</td>
<td>16.1</td>
</tr>
</tbody>
</table>

Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); NA, not applicable.
SI conversion factors: To convert cortisol to nmol/L, multiply by 27.588.
* While sedated; modified Frisen score, 0 to 5.

### Discussion
To our knowledge, this is the first case series reporting physiologic and anatomic findings associated with AI and PTCS, demonstrating that cortisol physiology is either a primary contributor or modulator of PTCS. This study provides clinical evidence supporting a neuroendocrine hypothesis underlying the pathogenesis of pediatric PTCS: inherent defects of the HPAA result in low basal cortisol production with reduced cerebrospinal fluid reabsorption and elevated ICP. R, O

This case series matches the prepubertal pediatric PTCS subgroup in terms of age, a lower preponderance of girls, subclinical presentation, and a low-grade papilledema. 3–6 All cases were consistent with the modified Dandy criteria except case 1; under the revised PTCS criteria, both case 1 and case 5 would be considered probable because of subthreshold OPs. 1, 2 Case 1 highlights the cyclical nature of GC withdrawal, papilledema, and then subsequent recovery. This case describes a distinctive clinical entity of episodic PTCS, in which incidental GC exposure and withdrawal cause mild AI with transient PTCS, depending on an individual’s HPAA capacity to recover. The postrecovery period lasts until a subsequent GC
At month 18, he had a low-dose Synacthen (peak cortisol) test (22.4 μg/dL) (to convert to nanomoles per liter, multiply by 27.588) and endocrine workup with negative results; at month 27, a reduction in steroid inhaler use (B); at month 32, an 8 AM cortisol test result of 5.8 μg/dL that confirmed adrenal insufficiency, for which hydrocortisone therapy was initiated. B-F, Specific points (corresponding to the letters in A) showing fundus and OCT images, with respective global mean thickness of the optic nerve peripapillary retinal nerve fiber layer (RNFL) in micrometers; Heidelberg-Spectralis OCT normative values for peripapillary RNFL global mean thickness for patients 4 to 18 years old are 104 ± 8.5 μm. G indicates global (360°); N, nasal; NL nasal inferior; NS, nasal superior; T, temporal; TI, temporal inferior; TS, temporal superior.

exposure or withdrawal, appearing as episodic bouts of PTCS. Depending on the timing of one’s ocular examination, true optic nerve edema with a normal OP may be identified, deviating from conventional PTCS criteria, leading to a misdiagnosis of pseudopapilledema or optic nerve drusen. This intermittent insult may occur in patients with allergy or atopy...
Association of Adrenal Insufficiency With Pediatric Pseudotumor Cerebri Syndrome

Brief Report Research

patients in this study had low basal 8 AM cortisol levels. Basal cortisol production variations could precipitate PTCS development, accounting for idiopathic causes (as in case 4) and other, secondary causative mechanisms (as in case 5). Moreover, if basal function is compromised with a normal capacity to stimulate cortisol (as in 2 of 5 cases in this study), PTCS may develop without symptoms of overt AI.

Diagnosis of AI is challenging; many factors affect cortisol testing results and patterns (eMethods in the Supplement). We recommend AI evaluation with either an 8 AM cortisol test or a LDST on initial evaluation of all children with PTCS and AI risk factors, no predisposing causes, or nonresponse to conventional treatment. Further management and treatment should be in combination with ophthalmology and endocrine services.

Strengths
Strengths include establishing biological plausibility for the neuroendocrine hypothesis and reporting sentinel events of unrecognized exposure associations. This study may facilitate new evaluation or treatment outcomes for pediatric PTCS.

Limitations
Limitations are inherent to the case series design. Possible confounders include a high male preponderance, alternative mechanism to PTCS resolution, and other underlying medical or genetic conditions affecting hypocortisolism or PTCS development.

Conclusions
This study provides clinical evidence for a neuroendocrine hypothesis involving the HPA axis in patients with prepubertal pediatric PTCS and highlights the association of exogenous GC with development of AI in episodic PTCS. It offers new recommendations to identify AI in PTCS and a causative mechanism-targeted treatment for improved outcomes.

ARTICLE INFORMATION
Accepted for Publication: July 16, 2020.
Published Online: September 17, 2020. doi:10.1001/jamaophthalmol.2020.3322

Author Contributions: Dr Shah had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: All authors.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: All authors.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Shah, Horne.

Administrative, technical, or material support: Hoyos-Martinez, Shah.

Supervision: Shah, Horne.

Conflict of Interest Disclosures: None reported.

Additional Contributions: We thank the patients’ families for granting permission to publish this study; as well as Jane Edmond, MD, Dell Medical School, University of Texas at Austin, whose patient care contributed to this study. She was not compensated for her contributions.

REFERENCES


jamaophthalmology.com

© 2020 American Medical Association. All rights reserved.

Published online September 17, 2020

JAMA Ophthalmology